Latest filings (excl ownership)
15-12G
Securities registration termination
8 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
29 Jan 24
POS AM
Prospectus update (post-effective amendment)
29 Jan 24
POS AM
Prospectus update (post-effective amendment)
29 Jan 24
POS AM
Prospectus update (post-effective amendment)
29 Jan 24
POS AM
Prospectus update (post-effective amendment)
29 Jan 24
POS AM
Prospectus update (post-effective amendment)
29 Jan 24
25
Voluntary exchange delisting
29 Jan 24
8-K
Entry into a Material Definitive Agreement
17 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
3 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
3 Oct 23
DEFR14A
Revised proxy
22 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Sep 23
DEF 14A
Definitive proxy
5 Sep 23
ARS
2022 FY
Annual report to shareholders
25 Aug 23
PRE 14A
Preliminary proxy
24 Aug 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
8-K
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
2 Aug 23
424B5
Prospectus supplement for primary offering
28 Jun 23
EFFECT
Notice of effectiveness
28 Jun 23
CORRESP
Correspondence with SEC
26 Jun 23
UPLOAD
Letter from SEC
23 Jun 23
S-3
Shelf registration
20 Jun 23
Latest ownership filings
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
4
Maria Carolina Petrini
11 Apr 23
3
Maria Carolina Petrini
11 Apr 23
SC 13G
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
4
Gail Frances McIntyre
2 Feb 23
4
Robert B. Geller
2 Feb 23
4
RUDY HOWARD
2 Feb 23
4
Leonard Scott Dove
2 Feb 23
SC 13D/A
Zhang Eric
28 Dec 22
SC 13D/A
Giaccia Amato
27 Dec 22
SC 13G
BIOTECHNOLOGY VALUE FUND L P
7 Nov 22
SC 13D/A
Eshelman Ventures, LLC
3 Nov 22
4/A
Peter Tai-Ching Ho
27 Oct 22
4/A
Eric Zhang
27 Oct 22
4
Amato Giaccia
26 Oct 22
4
Eric Zhang
26 Oct 22
4
RUDY HOWARD
26 Oct 22
4
Gail Frances McIntyre
26 Oct 22
4
Peter Tai-Ching Ho
26 Oct 22
4
FREDRIC N ESHELMAN
26 Oct 22
4
Sigurd Kirk
26 Sep 22
4
MICHAEL W ROGERS
26 Sep 22
4
Eric Zhang
26 Sep 22
4
FREDRIC N ESHELMAN
26 Sep 22
4
Amato Giaccia
26 Sep 22
4
Peter Tai-Ching Ho
26 Sep 22
4
John Hohneker
26 Sep 22
4
Robert B. Geller
5 Jul 22
3
Robert B. Geller
5 Jul 22
4
RUDY HOWARD
3 Jun 22
3
RUDY HOWARD
3 Jun 22
SC 13D/A
ESHELMAN FREDRIC N
5 Apr 22
4
FREDRIC N ESHELMAN
4 Apr 22
4
FREDRIC N ESHELMAN
31 Mar 22
4
Leonard Scott Dove
22 Mar 22
3
Leonard Scott Dove
22 Mar 22
SC 13G/A
New Leaf Biopharma Opportunities II, L.P.
11 Feb 22